biologics in develpoment - 2013 report

2013

REPORT Biologics Research Pushing Frontiers of Science With More Than 900 Medicines and Vaccines in Development Medicines in developMent

Biologics

presented By aMerica’s BiopharMaceutical research coMpanies Biologics In Development In the human body there are 12 trillion cells,

Medicines in Development Biologics 2013

2

Biologic Medicines in Development

A utoimmune D isorDers

Product Name

Sponsor

Product Category

Indication

Development Phase*

ABT-122

AbbVie

North Chicago, IL mAb

rheumatoid arthritis

Phase I 36c44e57c1c708a1294a4427

Actemra ? tocilizumab

Genentech

South San Francisco, CA Roche Nutley, NJ mAb early rheumatoid arthritis ------------------------------------------------systemic sclerosis

Phase III 36c44e57c1c708a1294a4427

--------------------------------Phase II 36c44e57c1c708a1294a4427

AGS-009Argos Therapeutics Durham, NC mAb

systemic lupus erythematosus (SLE)

Phase I

36c44e57c1c708a1294a4427 alemtuzumab Genzyme

Cambridge, MA mAb

relapsing-remitting multiple sclerosis (Fast Track)application submitted 36c44e57c1c708a1294a4427 Alferon N Injection ?interferon-alpha-n3subcutaneous Hemispherx Bioscience Philadelphia, PA interferon

multiple sclerosis

Phase II

36c44e57c1c708a1294a4427 AMG 557/MEDI-5872

Amgen

Thousand Oaks, CA AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD mAb SLE

Phase I 36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427

AMG 729Amgen

Thousand Oaks, CA mAb autoimmune diseases

Phase I 36c44e57c1c708a1294a4427 AMG 811 Amgen

Thousand Oaks, CA mAb

discoid lupus erythematosus, SLE

Phase I 36c44e57c1c708a1294a4427 anti-IL17 mAb (RG7624)Genentech

South San Francisco, CA mAb

autoimmune disorders

Phase I 36c44e57c1c708a1294a4427 anti-LINGO (BIIB033)

Biogen Idec Weston, MA mAb

multiple sclerosis (see also eye)Phase II

36c44e57c1c708a1294a4427 ARX424

(PEGylated interferon beta-1a) Ambrx

La Jolla, CA interferon

multiple sclerosis

Phase I 36c44e57c1c708a1294a4427 atacicept (TACI-lg)

EMD Serono Rockland, MA

recombinant fusion protein

SLE

Phase II/III 36c44e57c1c708a1294a4427

*For more information about a specific medicine or company in the report, please click on the provided link.

3

Biologic Medicines in Development

A utoimmune D isorDers

Product Name Sponsor Product

Category

Indication Development Phase

ATX-MS-1467EMD Serono

Rockland, MA peptide

vaccine

multiple sclerosis Phase I

36c44e57c1c708a1294a4427

AZ01

(long-acting pegylated interferon beta)Allozyne

Seattle, WA

interferon multiple sclerosis Phase I

36c44e57c1c708a1294a4427

Benlysta?belimumab (subcutaneous)GlaxoSmithKline

Rsch. Triangle Park, NC

mAb SLE

(see also blood, transplantation)

------------------------------------------------

systemic scleroderma

Phase III

36c44e57c1c708a1294a4427

--------------------------------

36c44e57c1c708a1294a4427

BHT-3009 Bayhill Therapeutics

Palo Alto, CA DNA

vaccine

multiple sclerosis Phase II

36c44e57c1c708a1294a4427

BI-695500 (rituximab biosimilar)Boehringer-Ingelheim

Pharmaceuticals

Ridgefield, CT

mAb rheumatoid arthritis Phase III

boehringer-ingelheim.

com

BI-695501 (adalimumab biosimilar)Boehringer Ingelheim

Pharmaceuticals

Ridgefield, CT

mAb rheumatoid arthritis Phase I

boehringer-ingelheim.

com

BIIB017 (PEG-interferon beta-1a)Biogen Idec

Weston, MA

interferon relapsing multiple sclerosis

(Fast Track)

Phase III

36c44e57c1c708a1294a4427

BT-061AbbVie

North Chicago, IL

Biotest

Dreieich, Germany mAb rheumatoid arthritis

(see also skin)

Phase II

36c44e57c1c708a1294a4427

biotest.de

Cimzia?certolizumab pegol UCB

Smyrna, GA

mAb ankylosing spondylitis,

juvenile rheumatoid arthritis

(see also musculoskeletal)

Phase III

36c44e57c1c708a1294a4427

clazakizumab (anti-IL6) Bristol-Myers Squibb

Princeton, NJ

Alder Biopharmaceuticals

Bothell, WA

mAb rheumatoid arthritis

(see also digestive,

musculoskeletal)

Phase II

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

CNTO-136 (sirukumab)Janssen Biotech

Horsham, PA

mAb rheumatoid arthritis

(see also other)

Phase III

36c44e57c1c708a1294a4427

CNTO-1959Janssen Biotech

Horsham, PA mAb rheumatoid arthritis

(see also skin)

Phase II

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

4

Biologic Medicines in Development

A utoimmune D isorDers

Product Name

Sponsor

Product Category

Indication

Development Phase

daclizumab

AbbVie

North Chicago, IL Biogen Idec Weston, MA mAb

multiple sclerosis (relapsing forms)

Phase III 36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 epratuzumab Immunomedics Morris Plains, NJ UCB

Smyrna, GA

mAb

SLE

(Fast Track)

Phase III

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 GSK1223249(NOGO-A mAb)GlaxoSmithKline

Rsch. Triangle Park, NC mAb

multiple sclerosis (see also neurologic)Phase I 36c44e57c1c708a1294a4427 Humira ? adalimumab

AbbVie

North Chicago, IL

mAb

rheumatoid arthritis (combination therapy) (see also digestive, eye, musculoskeletal, skin, other)Phase III 36c44e57c1c708a1294a4427

Ilaris ?

canakinumab (Orphan Drug)Novartis Pharmaceuticals East Hanover, NJ mAb

systemic juvenile idiopathic arthritis (see also cardiovascular, diabetes, musculoskeletal)Phase III 36c44e57c1c708a1294a4427 ISIS-CRP Rx Isis Pharmaceuticals Carlsbad, CA antisense

rheumatoid arthritis

(see also cardiovascular)Phase II

36c44e57c1c708a1294a4427 mavrilimumab

AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD mAb

rheumatoid arthritis

Phase II

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 MEDI-546

(anti-IFN-alphaR mAb)

AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD mAb SLE

Phase II

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 MEDI-551

(anti-CD19 mAb)

AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD mAb

scleroderma (see also cancer)

Phase I

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 MEDI-570

(anti-ICOS mAb)

AstraZeneca Wilmington, DE MedImmune Gaithersburg, MD

mAb SLE

Phase I

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427

5

Biologic Medicines in Development

A utoimmune D isorDers

Product Name Sponsor Product

Category

Indication Development Phase

NeuroVax?(IR208)Immune Response Biopharma

New York, NY

peptide

vaccine

multiple sclerosis Phase II

immuneresponsebio

36c44e57c1c708a1294a4427

NN8209

(anti-C5aR-151 mAb)Novo Nordisk

Princeton, NJ

mAb rheumatoid arthritis Phase II

36c44e57c1c708a1294a4427

NN8210

(anti-C5aR-215 mAb)Novo Nordisk

Princeton, NJ

mAb rheumatoid arthritis Phase I

36c44e57c1c708a1294a4427

NN8226 (anti-IL-20 mAb) Novo Nordisk

Princeton, NJ

mAb rheumatoid arthritis Phase II

36c44e57c1c708a1294a4427

NN8765 (anti-NKG2 mAb)Novo Nordisk

Princeton, NJ

mAb rheumatoid arthritis Phase I

36c44e57c1c708a1294a4427

NN8828 (anti-IL-21 mAb) Novo Nordisk

Princeton, NJ

mAb rheumatoid arthritis

--------------------------------

SLE

Phase II

36c44e57c1c708a1294a4427

--------------------------------

Phase I

36c44e57c1c708a1294a4427

Nplate? romiplostim (Orphan Drug)Amgen

Thousand Oaks, CA

recombinant

fusion

protein

immune thrombocytopenic

purpura in children

(see also cancer)

Phase III

36c44e57c1c708a1294a4427

NU-100 (interferon beta-1b)Nuron Biotech

Exton, PA

recombinant

interferon

multiple sclerosis Phase III

36c44e57c1c708a1294a4427

ocrelizumab (anti-CD20 mAb)Biogen Idec

Weston, MA

Genentech

South San Francisco, CA

Roche

Nutley, NJ

mAb primary-progressive multiple

sclerosis

------------------------------------------------

relapsing-remitting multiple

sclerosis

Phase III

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

---------------------------------

Phase III

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

ofatumumab (subcutaneous)GlaxoSmithKline

Rsch. Triangle Park, NC

mAb multiple sclerosis,

rheumatoid arthritis

Phase II

36c44e57c1c708a1294a4427

olokizumab UCB

Smyrna, GA mAb rheumatoid arthritis Phase II

36c44e57c1c708a1294a4427

Orencia?abatacept Bristol-Myers Squibb

Princeton, NJ

recombinant

fusion protein

early rheumatoid arthritis

(see also musculoskeletal, other)

Phase III

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

6

Biologic Medicines in Development

A utoimmune D isorDers

Product Name

Sponsor

Product Category

Indication

Development Phase

otelixizumab (anti-CD3 mAb)GlaxoSmithKline

Rsch. Triangle Park, NC mAb

rheumatoid arthritis

Phase I 36c44e57c1c708a1294a4427 ozoralizumab (ATN-103) Ablynx

Ghent, Belgium mAb rheumatoid arthritis

Phase II completed 36c44e57c1c708a1294a4427 pateclizumab

(anti-LT alpha mAb)Genentech

South San Francisco, CA mAb rheumatoid arthritis

Phase II 36c44e57c1c708a1294a4427 PD-360324

Pfizer

New York, NY

mAb cutaneous lupus erythematosus

Phase I 36c44e57c1c708a1294a4427

PDA-001 (cenplacel-L)Celgene Cellular Therapeutics Summit, NJ

stem cell therapy

rheumatoid arthritis (see also digestive)

------------------------------------------------multiple sclerosis, sarcoidosis Phase II 36c44e57c1c708a1294a4427

---------------------------------Phase I 36c44e57c1c708a1294a4427

PF-04236921

Pfizer

New York, NY

mAb

SLE

(see also digestive)

------------------------------------------------rheumatoid arthritis Phase II 36c44e57c1c708a1294a4427

---------------------------------Phase I 36c44e57c1c708a1294a4427 PF-05280586

(rituximab biosimilar)Pfizer

New York, NY mAb

rheumatoid arthritis

Phase I/II 36c44e57c1c708a1294a4427 plovamer acetate (second-generation peptide copolymer)EMD Serono Rockland, MA peptide multiple sclerosis

Phase I

36c44e57c1c708a1294a4427 Prolia ?

denosumab Amgen

Thousand Oaks, CA mAb

rheumatoid arthritis

(see also musculoskeletal)Phase II 36c44e57c1c708a1294a4427 RAVAX?

rheumatoid arthritis vaccine Immune Response BioPharma New York, NY

vaccine

rheumatoid arthritis

Phase III

immuneresponsebio 36c44e57c1c708a1294a4427 rontalizumab (RG7415)

Genentech

South San Francisco, CA mAb SLE

Phase II 36c44e57c1c708a1294a4427 SAN-300

(anti-VLA-1 antibody)

Santarus San Diego, CA

mAb

rheumatoid arthritis

Phase I

36c44e57c1c708a1294a4427

7

Biologic Medicines in Development

A utoimmune D isorDers

Product Name Sponsor Product

Category

Indication Development Phase

SAR113244 (anti-CXCR5 mAb)Sanofi US

Bridgewater, NJ

mAb SLE Phase I

36c44e57c1c708a1294a4427

sarilumab (SAR153191)Regeneron Pharmaceuticals

Tarrytown, NY

Sanofi US

Bridgewater, NJ

mAb rheumatoid arthritis Phase III

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

secukinumab (AIN457)Novartis Pharmaceuticals

East Hanover, NJ

mAb ankylosing spondylitis,

rheumatoid arthritis

(see also eye, musculoskeletal, skin)

------------------------------------------------

multiple sclerosis

Phase III

36c44e57c1c708a1294a4427

---------------------------------

Phase II

36c44e57c1c708a1294a4427

sifalimumab

(anti-IFN-alpha mAb) AstraZeneca

Wilmington, DE

MedImmune

Gaithersburg, MD

mAb SLE Phase II

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

Simponi?golimumab (Orphan Drug)Janssen Biotech

Horsham, PA

mAb rheumatoid arthritis

(intravenous)

(see also digestive)

------------------------------------------------

juvenile rheumatoid arthritis

(subcutaneous)

-----------------------------------------------

sarcoidosis

(subcutaneous)

application submitted

36c44e57c1c708a1294a4427

---------------------------------

Phase III

36c44e57c1c708a1294a4427

---------------------------------

Phase II completed

36c44e57c1c708a1294a4427

Soliris?eculizumab (Orphan Drug)Alexion Pharmaceuticals

Cheshire, CT

mAb severe or refractory myasthenia

gravis

(see also eye, infectious,

transplantation)

Phase II

36c44e57c1c708a1294a4427

Stelara?ustekinumab Janssen Biotech

Horsham, PA

mAb rheumatoid arthritis, sarcoidosis

(see also digestive,

musculoskeletal, other)

Phase II

36c44e57c1c708a1294a4427

tabalumab (BAFF inhibitor)Eli Lilly

Indianapolis, IN

mAb SLE

(see also cancer)

Phase III

36c44e57c1c708a1294a4427

Tcelna?imilecleucel-T Opexa Therapeutics

The Woodlands, TX

cell therapy

vaccine

multiple sclerosis

(Fast Track)

Phase II

36c44e57c1c708a1294a4427

Tysarbi?natalizumab Biogen Idec

Weston, MA

mAb secondary-progressive multiple

sclerosis

Phase III

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

8

Biologic Medicines in Development

A utoimmune D isorDers

Product Name

Sponsor

Product Category

Indication

Development Phase

veltuzumab (IMMU-106)

Immunomedics Morris Plains, NJ

Takeda Pharmaceuticals USA Deerfield, IL mAb

immune thrombocytopenic purpura, rheumatoid arthritis (see also cancer)Phase II

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 VX15Teva Pharmaceuticals Tikva, Israel Vaccinex

Rochester, NY mAb

multiple sclerosis (see also cancer)

Phase I

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 XmAb ?5871(anti-CD19 mAb)

Xencor

Monrovia, CA

mAb autoimmune disorders

Phase I 36c44e57c1c708a1294a4427

B looD D isorDers

Product Name

Sponsor

Product Category

Indication

Development Phase

ACE-536

Acceleron Pharma Cambridge, MA Celgene Summit, NJ

recombinant fusion protein anemia

Phase I

36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 ALXN1102/ALXN1103

Alexion Pharmaceuticals Cheshire, CT

recombinant fusion protein paroxysmal nocturnal hemoglobinuria Phase I 36c44e57c1c708a1294a4427 AMT-060(Orphan Drug)

uniQure

Amsterdam, The Netherlands St. Jude Children’s Research Hospital Memphis, TN

gene therapy

hemophilia B

Phase I/II 36c44e57c1c708a1294a4427

ART123

(recombinant human thrombomodulin alpha)Asahi Kasei Pharma America Waltham, MA

recombinant protein disseminated intravascular coagulation Phase III

36c44e57c1c708a1294a4427 AskBio009

Asklepios BioPharmaceutical Chapel Hill, NC Baxter International Deerfield, IL gene therapy

hemophilia B

Phase I/II 36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427 ATryn ?

antithrombin alfa (Orphan Drug)

GTC Biotherapeutics Framingham, MA

recombinant protein heparin resistance in patients under-going CABG surgery

Phase III 36c44e57c1c708a1294a4427

9

Biologic Medicines in Development

B looD D isorDers

Product Name Sponsor Product

Category

Indication Development Phase

BAX-111 (recombinant von Willebrand factor) (Orphan Drug)Baxter International

Deerfield, IL

recombinant

protein

von Willebrand disease Phase III

36c44e57c1c708a1294a4427

BAX-326 (rFIX) (Orphan Drug)Baxter International

Deerfield, IL

recombinant

protein

hemophilia B application submitted

36c44e57c1c708a1294a4427

BAX-817 (rFVIIa)Baxter International

Deerfield, IL

recombinant

protein

hemophilia A, hemophilia B Phase I/II

36c44e57c1c708a1294a4427

BAX-855 (rFVIII)Baxter International

Deerfield, IL

recombinant

protein

hemophilia A Phase I

36c44e57c1c708a1294a4427

BAY 86-6150 (rFVIIa)Bayer HealthCare

Pharmaceuticals

Wayne, NJ

recombinant

protein

hemophilia A, hemophilia B Phase II/III

36c44e57c1c708a1294a4427

BAY 94-9027 (rFVIII)Bayer HealthCare

Pharmaceuticals

Wayne, NJ

recombinant

protein

hemophilia A Phase II/III

36c44e57c1c708a1294a4427

Benlysta?belimumab (oral)GlaxoSmithKline

Rsch. Triangle Park, NC

mAb vasculitis

(see also autoimmune,

transplantation)

Phase I completed

36c44e57c1c708a1294a4427

beta-globin gene therapy (lentiglobin)bluebird bio

Cambridge, MA

INSERM

Paris, France

gene

therapy

beta-thalassemia,

sickle cell anemia

Phase I/II

36c44e57c1c708a1294a4427

BI-655075Boehringer Ingelheim

Pharmaceuticals

Ridgefield, CT mAb blood coagulation disorders Phase I

boehringer-ingelheim.

com

CSL-627 (rVIII-SC)CSL Behring

King of Prussia, PA

recombinant

protein

hemophilia A Phase I

36c44e57c1c708a1294a4427

CSL-654 (rIX-FP) (Orphan Drug)CSL Behring

King of Prussia, PA

recombinant

fusion

protein

hemophilia B Phase II/III

36c44e57c1c708a1294a4427

CSL-689 (rVIIa-FP) (Orphan Drug)CSL Behring

King of Prussia, PA

recombinant

fusion

protein

hemophilia A, hemophilia B Phase I

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

10

Biologic Medicines in Development

B looD D isorDers

Product Name

Sponsor

Product Category

Indication

Development Phase

CYT107

(interleukin-7)

Cytheris

Rockville, MD

recombinant interleukin

idiopathic CD4-positive lymphocytopenia

(see also cancer, infectious, transplantation)Phase I/II 36c44e57c1c708a1294a4427

epoetin alfa biosimilar

Hospira

Lake Forest, IL recombinant erythropoietin anemia

Phase III 36c44e57c1c708a1294a4427 erythropoietin gene therapy Medgenics

San Francisco, CA gene therapy

anemia

Phase II

36c44e57c1c708a1294a4427 factor VIII/von Willebrand factor CSL Behring

King of Prussia, PA recombinant protein hemophilia A,

von Willebrand disease Phase III

36c44e57c1c708a1294a4427 ferroportin mAb

Eli Lilly

Indianapolis, IN mAb

anemia

Phase I 36c44e57c1c708a1294a4427 hepcidin mAb Eli Lilly

Indianapolis, IN mAb anemia

Phase I 36c44e57c1c708a1294a4427 HM10760A

Hanmi Pharmaceutical Seoul, South Korea long-acting erythropoietin anemia

Phase I

36c44e57c1c708a1294a4427 human

recombinant factor VIII Octapharma USA Hoboken, NJ

recombinant protein hemophilia A

Phase II

36c44e57c1c708a1294a4427 IB1001

(recombinant factor IX biosimilar)Inspiration Biopharmaceuticals Cambridge, MA Ipsen

Paris, France recombinant protein

hemophilia B

application submitted 36c44e57c1c708a1294a4427

ISIS-FXI Rx

Isis Pharmaceuticals Carlsbad, CA antisense clotting disorders

Phase II

36c44e57c1c708a1294a4427 NAV? therapeutic

ReGenX Biosciences Washington, DC gene therapy

hemophilia B (see also genetic)Phase I/II 36c44e57c1c708a1294a4427 NiCord ?

umbilical cord blood stem cell therapy Gamida Cell Jerusalem, Israel stem cell therapy sickle cell anemia (see also cancer)

Phase I/II

36c44e57c1c708a1294a4427 NN1841(rFXIII)Novo Nordisk Princeton, NJ recombinant protein congenital factor XIII deficiency

application submitted 36c44e57c1c708a1294a4427 NN7008

(turoctocog alfa)

Novo Nordisk Princeton, NJ

recombinant protein

hemophilia A

application submitted 36c44e57c1c708a1294a4427

11

Biologic Medicines in Development

B looD D isorDers

Product Name Sponsor Product

Category

Indication Development Phase

NN7088

(N8-GP, rFVIII glycopegylated)Novo Nordisk

Princeton, NJ

recombinant

protein

hemophilia A Phase III

36c44e57c1c708a1294a4427

NN7999

(N9-GP, rFIX glycopegylated)Novo Nordisk

Princeton, NJ

recombinant

protein

hemophilia B Phase III

36c44e57c1c708a1294a4427

OBI-1 (recombinant porcine factor VIII) (Orphan Drug)Inspiration Biopharmaceuticals

Cambridge, MA

Ipsen

Paris, France

recombinant

protein

hemophilia A

(Fast Track)

Phase III

36c44e57c1c708a1294a4427

PF-05280602 (rhFVIIa)Catalyst Biosciences

South San Francisco, CA

Pfizer

New York, NY

recombinant

protein

hemophilia Phase I

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

PRT4445

(FXa inhibitor antidote)Portola Pharmaceuticals

South San Francisco, CA

recombinant

protein

hemorrhage Phase II

36c44e57c1c708a1294a4427

recombinant factor VIII-Fc (Orphan Drug)Biogen Idec

Weston, MA

recombinant

fusion

protein

hemophilia A

(Fast Track)

Phase III

36c44e57c1c708a1294a4427

recombinant factor IX-Fc (Orphan Drug)Biogen Idec

Weston, MA

recombinant

fusion

protein

hemophilia B

(Fast Track)

-----------------------------------------------

hemophilia B in children

(Fast Track)

application submitted

36c44e57c1c708a1294a4427

---------------------------------

Phase III

36c44e57c1c708a1294a4427

SelG1Selexys Pharmaceuticals

Oklahoma City, OK mAb sickle cell anemia Phase I completed

36c44e57c1c708a1294a4427

sotatercept (ACE-011)Acceleron Pharma

Cambridge, MA

Celgene

Summit, NJ

recombinant

fusion

protein

anemia in patients with end-stage

renal disease

(see also cancer)

Phase II

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

TT-173Thrombotargets

Durham, NC recombinant

protein

blood coagulation disorders Phase I

36c44e57c1c708a1294a4427

Wilate?

von Willebrand factor/ coagulation factor VIII complex (human)Octapharma USA

Hoboken, NJ

recombinant

protein

surgical blood loss Phase III

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

12

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name

Sponsor

Product Category

Indication

Development Phase

8H9 mAb

United Therapeutics Silver Spring, MD mAb

metastatic brain cancer

Phase I 36c44e57c1c708a1294a4427 212-Pb-TCMC- trastuzumab AREVA Med Bethesda, MD

mAb

HER2-positive cancer metastasized to the abdominal region Phase I

36c44e57c1c708a1294a4427 AbGn-7

AbGenomics International Los Altos, CA mAb

solid tumors

Phase I

ABIO-0501(TALL-104)Abiogen Pharma Pisa, Italy cell therapy chronic myeloid leukemia (CML)

Phase II abiogen.it ABT-806

AbbVie

North Chicago, IL mAb solid tumors

Phase I 36c44e57c1c708a1294a4427 Actimab-A (M195 mAb) Actinium Pharmaceuticals New York, NY mAb acute myeloid leukemia (AML)

Phase I/II

actiniumpharmaceuti 36c44e57c1c708a1294a4427

Adcetris ?

brentuximab vedotin (Orphan Drug)

Seattle Genetics Bothell, WA

mAb

cutaneous T-cell lymphoma, front-line Hodgkin lymphoma,

post-transplant Hodgkin lymphoma relapse prevention

------------------------------------------------non-Hodgkin lymphoma,

non-lymphoma malignancies, CD30-positive hematologic

malignancies, CD30-positive T-cell lymphoma Phase III

36c44e57c1c708a1294a4427 ---------------------------------Phase II

36c44e57c1c708a1294a4427

AD-IL-12

ZIOPHARM Oncology New York, NY gene therapy

malignant melanoma

Phase I/II 36c44e57c1c708a1294a4427 ADI-PEG-20

Polaris Pharmaceuticals San Diego, CA

pegylated protein

liver cancer

------------------------------------------------malignant melanoma, mesothelioma, small-cell lung cancer (SCLC)

Phase III

36c44e57c1c708a1294a4427

---------------------------------Phase II

36c44e57c1c708a1294a4427 ADXS-HPV

Advaxis

Princeton, NJ vaccine

cervical cancer, cervical intraepithelial neoplasia Phase II 36c44e57c1c708a1294a4427 AE08

Antigen Express Worcester, MA peptide vaccine malignant melanoma

Phase I

36c44e57c1c708a1294a4427 AE37 Antigen Express Worcester, MA

peptide vaccine

breast cancer

Phase II

36c44e57c1c708a1294a4427

13

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name Sponsor Product

Category

Indication Development Phase

AGS-003 Argos Therapeutics

Durham, NC personalized

dendritic cell

vaccine

metastatic renal cancer

(Fast Track)

Phase III

36c44e57c1c708a1294a4427

ALD-151Cytomedix

Gaithersburg, MD

Duke University

Durham, NC stem cell

therapy

leukemia Phase I completed

36c44e57c1c708a1294a4427

AlloStim?cancer vaccine Immunovative Therapies

Shoham, Israel

cell vaccine hematological malignancies,

solid tumors

Phase I/II

immunovative.co.il

Allovectin?velimogene aliplasmid (Orphan Drug)Vical

San Diego, CA

DNA

immunothera-

peutic

malignant melanoma

(Fast Track)

Phase III

36c44e57c1c708a1294a4427

ALN-VSP Alnylam Pharmaceuticals

Cambridge, MA RNA

interference

liver cancer, liver metastases Phase I

36c44e57c1c708a1294a4427

ALT-801 Altor BioScience

Miramar, FL recombinant

fusion

protein

AML, bladder cancer, malignant

melanoma, multiple myeloma

Phase I/II

36c44e57c1c708a1294a4427

ALT-836Altor BioScience

Miramar, FL

Genentech

South San Francisco, CA mAb cancer

(see also respiratory)

Phase I/II

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

AME-133v MENTRIK Biotech

Dallas, TX mAb non-Hodgkin lymphoma Phase II

36c44e57c1c708a1294a4427

AMG 386 Amgen

Thousand Oaks, CA recombinant

fusion

protein

fallopian tube cancer,

ovarian cancer, peritoneal cancer

------------------------------------------------

breast cancer, colorectal cancer,

gastric cancer, liver cancer,

esophageal cancer, renal cancer

Phase III

36c44e57c1c708a1294a4427

---------------------------------

Phase II

36c44e57c1c708a1294a4427

AMG 780Amgen

Thousand Oaks, CA antibody solid tumors Phase I

36c44e57c1c708a1294a4427

AMG 820Amgen

Thousand Oaks, CA mAb solid tumors Phase I

36c44e57c1c708a1294a4427

AMG 888 (U3-1287) Amgen

Thousand Oaks, CA

U3 Pharma

Martinsried, Germany

mAb non-small-cell lung cancer (NSCLC)Phase II

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

14

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name

Sponsor

Product Category

Indication

Development Phase

antibody-drug conjugate (RG7600)

Genentech

South San Francisco, CA mAb

ovarian cancer, pancreatic cancer

Phase I 36c44e57c1c708a1294a4427 anti-CD3-anti-HER2/neu-activated T-cells

TransTarget Hillsborough, CA

Barbara Ann Karmanos Cancer Institute Detroit, MI

cell therapy

metastatic breast cancer

Phase II

anti-CD22 ADC (RG7593)

Genentech

South San Francisco, CA Seattle Genetics Bothell, WA

mAb

diffuse large B-cell lymphoma, non-Hodgkin lymphoma

------------------------------------------------chronic lymphocytic leukemia (CLL)Phase II 36c44e57c1c708a1294a4427

--------------------------------Phase I 36c44e57c1c708a1294a4427

anti-CD45 mAb Actinium Pharmaceuticals New York, NY

mAb

AML

Phase I

actiniumpharmaceuti 36c44e57c1c708a1294a4427

anti-CD79b ADC (RG7596)

Genentech

South San Francisco, CA Seattle Genetics Bothell, WA mAb

diffuse large B-cell lymphoma, non-Hodgkin lymphoma

------------------------------------------------CLL

Phase II 36c44e57c1c708a1294a4427

---------------------------------Phase I 36c44e57c1c708a1294a4427 anti-CXCR4Bristol-Myers Squibb Princeton, NJ

mAb

hematological malignancies

Phase I 36c44e57c1c708a1294a4427

anti-EGFL7 mAb (RG7414)

Genentech

South San Francisco, CA

mAb

metastatic colorectal cancer, NSCLC

------------------------------------------------solid tumors Phase II 36c44e57c1c708a1294a4427

--------------------------------Phase I 36c44e57c1c708a1294a4427 anti-FGFR3 mAb (RG7444) Genentech

South San Francisco, CA mAb

solid tumors

Phase I 36c44e57c1c708a1294a4427 anti-HER3/EGFR DAF mAb (RG7597) Genentech

South San Francisco, CA mAb

colorectal cancer, head and neck cancer Phase II 36c44e57c1c708a1294a4427 anti-PD-L1

Bristol-Myers Squibb Princeton, NJ

mAb cancer

(see also infectious)Phase I 36c44e57c1c708a1294a4427 anti-PD-L1 mAb (RG7446)Genentech

South San Francisco, CA mAb

melanoma, solid tumors

Phase I 36c44e57c1c708a1294a4427 anti-STEAP1 ADC (RG7450)

Genentech

South San Francisco, CA Seattle Genetics Bothell, WA

mAb prostate cancer

Phase I 36c44e57c1c708a1294a4427

15

Biologic Medicines in Development

C anCer and r elated C onditions

Product Name Sponsor Product

Category

Indication Development Phase

APN301 (hu14.18-IL2) Apeiron Biologics

Vienna, Austria

mAb malignant melanoma,

neuroblastoma in children

Phase II completed

36c44e57c1c708a1294a4427

Archexin? RX-0201 (Orphan Drug)Rexahn Pharmaceuticals

Rockville, MD

antisense pancreatic cancer Phase II

36c44e57c1c708a1294a4427

Arzerra?ofatumumab (Orphan Drug)GlaxoSmithKline

Rsch. Triangle Park, NC

mAb CLL (first-line therapy),

diffuse large B-cell lymphoma,

follicular lymphoma

Phase III

36c44e57c1c708a1294a4427

ASC-101 (Orphan Drug)America Stem Cell

Carlsbad, CA

stem cell

therapy

myeloablation associated with

hematological malignancies

Phase I/II

36c44e57c1c708a1294a4427

ASG-5ME Agensys

Santa Monica, CA

Seattle Genetics

Bothell, WA mAb-drug

conjugate

pancreatic cancer,

castration-resistant

prostate cancer

Phase I

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

ASG-22ME Agensys

Santa Monica, CA

Seattle Genetics

Bothell, WA mAb-drug

conjugate

solid tumors Phase I

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

autologous stem cell therapy California Stem Cell

Irvine, CA

stem cell

therapy

malignant melanoma Phase II

36c44e57c1c708a1294a4427

AV-203AVEO Oncology

Cambridge, MA mAb solid tumors Phase I

36c44e57c1c708a1294a4427

Avastin?bevacizumab (Orphan Drug)Genentech

South San Francisco, CA

Roche

Nutley, NJ

mAb ovarian cancer

------------------------------------------------

HER-2 negative-breast cancer,

HER-2 positive breast cancer, high-

risk carcinoid tumors, glioblastoma

multiforme, metastatic ovarian

cancer, NSCLC

application submitted

36c44e57c1c708a1294a4427

---------------------------------

Phase III

36c44e57c1c708a1294a4427

AVX701 AlphaVax

Rsch. Triangle Park, NC virus replicon

particle

vaccine

CEA-expressing colorectal cancer Phase I/II

36c44e57c1c708a1294a4427

AVX901AlphaVAx

Rsch. Triangle Park, NC virus replicon

particle

vaccine

HER2-expressing breast cancer Phase I

36c44e57c1c708a1294a4427

B7-2/GM-CSF cancer gene therapy (combination immunogene therapy)NuVax Therapeutics

(Radient Pharmaceuticals)

Tustin, CA

gene

therapy

cancer Phase I

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

16

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name

Sponsor

Product Category

Indication

Development Phase

bavituximab

Peregrine Pharmaceuticals Tustin, CA

mAb

NSCLC, pancreatic cancer ------------------------------------------------breast cancer, liver cancer, prostate cancer, rectal adenocarcinoma

Phase II

36c44e57c1c708a1294a4427

--------------------------------Phase I/II

36c44e57c1c708a1294a4427 BAX-69

Baxter International Deerfield, IL mAb

solid tumors (see also other)Phase I 36c44e57c1c708a1294a4427 BAY 79-4620 Bayer HealthCare Pharmaceuticals Wayne, NJ mAb

solid tumors

Phase I

36c44e57c1c708a1294a4427 BAY 94-9343Bayer HealthCare Pharmaceuticals Wayne, NJ mAb solid tumors

Phase I

36c44e57c1c708a1294a4427 BAY 20-10112Amgen

Thousand Oaks, CA Bayer HealthCare Pharmaceuticals Wayne, PA

mAb solid tumors

Phase I 36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

BC-819

(Orphan Drug)BioCancell Therapeutics Jerusalem, Israel

gene therapy

bladder cancer, pancreatic cancer (Fast Track)

------------------------------------------------ovarian cancer Phase II

36c44e57c1c708a1294a4427

---------------------------------Phase I/II 36c44e57c1c708a1294a4427 BHQ880

Novartis Pharmaceuticals East Hanover, NJ mAb

multiple myeloma

Phase II 36c44e57c1c708a1294a4427 BI-505

(Orphan Drug)BioInvent International Lund, Sweden mAb multiple myeloma

Phase I

36c44e57c1c708a1294a4427 BI-836845

Boehringer Ingelheim Pharmaceuticals Ridgefield, CT mAb solid tumors

Phase I

36c44e57c1c708a1294a4427

BiovaxID ?

B-cell lymphoma vaccine Biovest International Tampa, FL

autologous idiotype vaccine

follicular lymphoma (Fast Track)

------------------------------------------------mantle-cell lymphoma Phase III 36c44e57c1c708a1294a4427

---------------------------------Phase II 36c44e57c1c708a1294a4427 blinatumomab (Orphan Drug)Amgen

Thousand Oaks, CA mAb

leukemia and lymphoma

Phase II 36c44e57c1c708a1294a4427 BP-100-1.01(liposomal Grb-2)

Bio-Path Holdings Houston, TX

antisense

acute lymphocytic leukemia (ALL), AML, CML,

myelodysplastic syndromes

Phase I

36c44e57c1c708a1294a4427

17

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name Sponsor Product

Category

Indication Development Phase

BPX-101Bellicum Pharmaceuticals

Houston, TX dendritic cell

vaccine

prostate cancer Phase I/II

36c44e57c1c708a1294a4427

breast cancer vaccine MabVax Therapeutics

San Diego, CA mAb vaccine breast cancer Phase I

36c44e57c1c708a1294a4427

BT-062 (indatuximab ravtansine) (Orphan Drug)Biotest

Dreieich, Germany

mAb multiple myeloma Phase I/II

biotest.de

BYM338Novartis Pharmaceuticals

East Hanover, NJ mAb cancer-related cachexia

(see also musculoskeletal)

Phase II

36c44e57c1c708a1294a4427

CALAA-01Calando Pharmaceuticals

Pasadena, CA RNA

interference

solid tumors Phase I

36c44e57c1c708a1294a4427

calaspargase pegol Sigma-Tau Pharmaceuticals

Gaithersburg, MD pegylated

enzyme

ALL in adolescents and children Phase III

36c44e57c1c708a1294a4427

cancer medicine Eli Lilly

Indianapolis, IN biologic cancer Phase I

36c44e57c1c708a1294a4427

cancer medicine Eli Lilly

Indianapolis, IN biologic cancer Phase I

36c44e57c1c708a1294a4427

cancer vaccine Bayer HealthCare

Pharmaceuticals

Wayne, NJ

Stellar Biotechnologies

Port Hueneme, CA autologous

idiotype

vaccine

follicular lymphoma Phase I

36c44e57c1c708a1294a4427

cancer vaccine EMD Millipore

Billerica, MA dendritic cell

vaccine

malignant melanoma Phase I completed

36c44e57c1c708a1294a4427

cancer vaccine Gradalis

Carrollton, TX

Mary Crowley Cancer

Research Center

Dallas, TX genetically-

modified

vaccine

solid tumors Phase I

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

cancer vaccine Immunitor

Vancouver, Canada vaccine cancer Phase I/II

36c44e57c1c708a1294a4427

cancer vaccine (AdhTAP)TapImmune

Seattle, WA

therapeutic

vaccine

breast cancer Phase I

36c44e57c1c708a1294a4427

catumaxomab Fresenius Biotech

North America

Waltham, MA mAb malignant ascites,

ovarian cancer

Phase II completed

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

18

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name

Sponsor

Product Category

Indication

Development Phase

CDX-011

(glembatumumab vedotin)Celldex Therapeutics Needham, MA mAb

breast cancer (Fast Track), malignant melanoma Phase II

36c44e57c1c708a1294a4427 CDX-1127

Celldex Therapeutics Needham, MA mAb

hematological malignancies, solid tumors Phase I

36c44e57c1c708a1294a4427 CDX-1401

Celldex Therapeutics Needham, MA

mAb vaccine solid tumors

Phase I/II

36c44e57c1c708a1294a4427 cell therapy

Cell Medica

London, United Kingdom

Center for Cell and Gene Therapy Houston, TX

cell therapy

cancer

(see also infectious)

Phase II

36c44e57c1c708a1294a4427

CEP-37250/KNK-2804Teva North America North Wales, PA

Kyowa Hakko Kirin Pharma Princeton, NJ mAb adenocarcinoma

Phase I

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427 CG201

(anti-hCG vaccine)CG Therapeutics Seattle, WA antibody vaccine solid tumors

Phase II

36c44e57c1c708a1294a4427 ch14.18 mAb (Orphan Drug)United Therapeutics Silver Spring, MD mAb

neuroblastoma

Phase III 36c44e57c1c708a1294a4427 cixutumumab (LY3012217)

Eli Lilly

Indianapolis, IN Imclone Systems Princeton, NJ mAb NSCLC

Phase II 36c44e57c1c708a1294a4427

CLT-008

Cellerant Therapeutics San Carlos, CA cell therapy chemotherapy-induced neutropenia (see also transplantation)Phase I/II 36c44e57c1c708a1294a4427 CNTO-328 (siltuximab)

Janssen Biotech Horsham, PA

mAb

giant lymph node hyperplasia, multiple myeloma, myelodysplastic syndromes

------------------------------------------------prostate cancer Phase II

36c44e57c1c708a1294a4427 ---------------------------------Phase I

36c44e57c1c708a1294a4427 Cotara ? mAb TNT (Orphan Drug)Peregrine Pharmaceuticals Tustin, CA mAb

recurrent glioblastoma (Fast Track)Phase II

36c44e57c1c708a1294a4427 CRS-207

Aduro Biotech Berkeley, CA

genetically-modified vaccine

pancreatic cancer

------------------------------------------------mesothelioma

Phase II

36c44e57c1c708a1294a4427

---------------------------------Phase I

36c44e57c1c708a1294a4427

19

Biologic Medicines in Development

C anCer and r elated C onditions

Product Name Sponsor Product

Category

Indication Development Phase

CSF-1R mAb (IMC-CS4)Eli Lilly

Indianapolis, IN

ImClone Systems

Bridgewater, NJ

mAb solid tumors Phase I

36c44e57c1c708a1294a4427

CT-011 (pidilizumab)CureTech

Yavne, Israel

mAb AML, colorectal cancer, diffuse

large B-cell lymphoma, follicular

lymphoma, malignant melanoma

Phase II

36c44e57c1c708a1294a4427

CTL019Novartis

East Hanover, NJ

University of Pennsylvania

Philadelphia, PA cell therapy CLL Phase II

36c44e57c1c708a1294a4427

custirsen (OGX-011) OncoGenex Technologies

Vancouver, Canada

Teva Pharmaceuticals

Tikva, Israel

antisense NSCLC, prostate cancer

(Fast Track)

------------------------------------------------

first-time NSCLC

Phase III

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

---------------------------------

Phase II

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

CV-301BN ImmunoTherapeutics

Mountain View, CA cancer

vaccine

metastatic breast cancer Phase II

36c44e57c1c708a1294a4427

CVac?

cancer vaccine MUC-1Prima BioMed

Melbourne, Australia

personalized

dendritic cell

vaccine

ovarian cancer Phase II/III

36c44e57c1c708a1294a4427.au

CYT107 (interleukin-7)Cytheris

Rockville, MD

recombinant

interleukin

malignant melanoma, renal cancer

(see also blood, infectious,

transplantation)

Phase I

36c44e57c1c708a1294a4427

CYT-6091 (Aurimune?)Cytimmune Sciences

Rockville, MD

tumor

necrosis

factor

solid tumors Phase I

36c44e57c1c708a1294a4427

dalotuzumab (MK-0646)Merck

Whitehouse Station, NJ

mAb breast cancer, neuroendocrine

tumors, NSCLC

Phase II

36c44e57c1c708a1294a4427

daratumumab Janssen Biotech

Horsham, PA mAb multiple myeloma Phase I/II

36c44e57c1c708a1294a4427

DC-IL-12ZIOPHARM Oncology

New York, NY cell

therapy

malignant melanoma Phase I

36c44e57c1c708a1294a4427

DCVax?-L

brain cancer vaccine (Orphan Drug)Northwest Biotherapeutics

Bethesda, MD

dendritic cell

vaccine

glioblastoma Phase III

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

Medicines in Development Biologics 2013

20

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name

Sponsor

Product Category

Indication

Development Phase

DEDN6526A

(antibody drug conjugate)Genentech

South San Francisco, CA mAb

malignant melanoma

Phase I 36c44e57c1c708a1294a4427 demcizumab (OMP-21M18)

GlaxoSmithKline

Rsch. Triangle Park, NC OncoMed Pharmaceuticals Redwood City, CA mAb solid tumors

Phase I 36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427 DFRF4539A Genentech

South San Francisco, CA mAb multiple myeloma

Phase I 36c44e57c1c708a1294a4427 DI17E6

(anti-integrin mAb)EMD Serono Rockland, MA mAb colorectal cancer, prostate cancer

Phase II

36c44e57c1c708a1294a4427 DKN-01

Dekkun

Cambridge, MA mAb solid tumors

Phase I

DN24-02

Dendreon Seattle, WA personalized dendritic cell vaccine HER2-positive urogenital cancer

Phase II

36c44e57c1c708a1294a4427 DPX-0907

Immunovaccine Halifax, Canada vaccine

breast cancer, ovarian cancer,prostate cancer Phase I

36c44e57c1c708a1294a4427 DPX-Survivac

Immunovaccine Halifax, Canada peptide vaccine ovarian cancer

Phase I/II 36c44e57c1c708a1294a4427 EC17

Endocyte

West Lafayette, IN

vaccine

renal cancer

(combination therapy)Phase I

36c44e57c1c708a1294a4427 ecromeximab (KW-2871)Life Science Pharmaceuticals Darien, CT mAb

metastatic melanoma

Phase II

36c44e57c1c708a1294a4427 EGEN-001 (Orphan Drug)

EGEN

Huntsville, AL

gene therapy

ovarian cancer

------------------------------------------------colorectal cancer

Phase II 36c44e57c1c708a1294a4427

---------------------------------Phase I/II 36c44e57c1c708a1294a4427 elotuzumab

Bristol-Myers Squibb Princeton, NJ AbbVie

North Chicago, IL

mAb multiple myeloma

Phase III 36c44e57c1c708a1294a4427 36c44e57c1c708a1294a4427

21

Biologic Medicines in Development

C AnCer An

D r elAteD C onDitions

Product Name Sponsor Product

Category

Indication Development Phase

enavatuzumab AbbVie

North Chicago, IL mAb solid tumors Phase I completed

36c44e57c1c708a1294a4427

encapsulated cell therapy Metromedia Bio-Science

New York, NY

Rogosin Institute

New York, NY cell

therapy

colorectal cancer, pancreatic

cancer, prostate cancer

Phase II

36c44e57c1c708a1294a4427

encapsulated cell therapy Nuvilex

Silver Spring, MD cell

therapy

pancreatic cancer Phase II

36c44e57c1c708a1294a4427

ensituximab (NPC-1C)Neogenix Oncology

Great Neck, NY

mAb colorectal cancer,

pancreatic cancer

Phase I

36c44e57c1c708a1294a4427

entolimod (CBLB502)Cleveland BioLabs

Buffalo, NY

engineered

peptide

radiation damage in cancer patients

(see also other)

Phase I

36c44e57c1c708a1294a4427

epratuzumab Y-90/ veltuzumab combination Immunomedics

Morris Plains, NJ

mAb non-Hodgkin lymphoma Phase I/II

36c44e57c1c708a1294a4427

Erbitux?cetuximab Bristol-Myers Squibb

Princeton, NJ

Eli Lilly

Indianapolis, IN

ImClone Systems

Princeton, NJ

mAb esophageal cancer Phase III

36c44e57c1c708a1294a4427

36c44e57c1c708a1294a4427

ETBX-011Etubics

Seattle, WA vector

vaccine

colon cancer Phase II

36c44e57c1c708a1294a4427

EZN-2968Enzon Pharmaceuticals

Piscataway, NJ antisense lymphoma, solid tumors Phase I

36c44e57c1c708a1294a4427

EZN-4176Enzon Pharmaceuticals

Piscataway, NJ antisense prostate cancer Phase I

36c44e57c1c708a1294a4427

F-627Generon

Shanghai, China recombinant

fusion protein

chemotherapy-induced neutropenia Phase II

36c44e57c1c708a1294a4427

Fang? Vaccine autologous tumor cell vaccine Gradalis

Carrollton, TX

autologous

cell vaccine

solid tumors Phase II

36c44e57c1c708a1294a4427

Medicines in Development Biologics2013

本文来源：https://www.bwwdw.com/article/phne.html